Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors
Brief Summary: RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells. If is not yet known which treatment regimen is most effective for breast cancer.

PURPOSE: Randomized double-blind phase III trial to compare the effectiveness of letrozole with that of tamoxifen in treating postmenopausal women who have breast cancer that has been surgically removed.


Options:
A: Arm Label: Tamoxifen; Type: EXPERIMENTAL; Interventions: Drug: tamoxifen citrate | Arm Label: Letrozole; Type: EXPERIMENTAL; Interventions: Drug: letrozole | Arm Label: Tamoxifen, then letrozole; Type: EXPERIMENTAL; Interventions: Drug: letrozole, Drug: tamoxifen citrate | Arm Label: Letrozole, then tamoxifen; Type: EXPERIMENTAL; Interventions: Drug: letrozole, Drug: tamoxifen citrate | Intervention Type: DRUG; Name: letrozole; Assigned to Arm(s): Letrozole, Letrozole, then tamoxifen, Tamoxifen, then letrozole | Intervention Type: DRUG; Name: tamoxifen citrate; Assigned to Arm(s): Letrozole, then tamoxifen, Tamoxifen, Tamoxifen, then letrozole
B: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: testosterone | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: testosterone; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
C: Arm Label: Arm I/Group A (Duloxetine then Placebo); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Arm Label: Arm II/Group B (Placebo then Duloxetine); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine)
D: Arm Label: Tamoxifen; Type: ACTIVE_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Drug: Tamoxifen | Arm Label: T+OFS; Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Procedure: Oophorectomy, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Drug: Tamoxifen, Drug: Triptorelin | Arm Label: E+OFS; Type: EXPERIMENTAL; Interventions: Drug: Exemestane, Other: Laboratory Biomarker Analysis, Procedure: Oophorectomy, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Drug: Triptorelin | Intervention Type: DRUG; Name: Exemestane; Assigned to Arm(s): E+OFS | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): E+OFS, T+OFS, Tamoxifen | Intervention Type: PROCEDURE; Name: Oophorectomy; Assigned to Arm(s): E+OFS, T+OFS | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): E+OFS, T+OFS, Tamoxifen | Intervention Type: RADIATION; Name: Radiation Therapy; Assigned to Arm(s): E+OFS, T+OFS | Intervention Type: DRUG; Name: Tamoxifen; Assigned to Arm(s): T+OFS, Tamoxifen | Intervention Type: DRUG; Name: Triptorelin; Assigned to Arm(s): E+OFS, T+OFS

Answer: A